it's a startup Pharma. of course they have diluted in the past, that is why the chart looks that way. if they have revs now the need to dilute will not be there.
so they do not need FDA approval to go up, they need more licensing deals and revs.
so i guess you will just be here for play by play and not buy since it will just keep going down? always good to have a sportscaster on the team. good lcuk
show me a R&D biotech that has positive earnings while they are working on their drug that people are buying stock in? those trade between 2 and 5 bucks a stub....
Just sayin.......
It's not a R/S... It's a new share class intended to trade along side of these R&D biotechs......
News 
Market Data 
Discover 
AI
